12:00 AM
 | 
Jun 17, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Selinexor: Phase I data

Additional data from 26 patients in the dose-escalation portion of an open-label, international Phase I trial showed that oral selinexor was generally well tolerated up to the MTD of 30 mg/m 2. Dose-limiting toxicities (DLTs) at the 40 mg/m 2 dose included grade 3 anorexia, dehydration and fatigue. The most common...

Read the full 233 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >